Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cosyntropin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.74 |
| ▸ | MC4R | P32245 | 3/20 | 0.72 |
| ▸ | MC5R | P33032 | 2/20 | 0.72 |
| ▸ | MC3R | P41968 | 2/20 | 0.72 |
| ▸ | MC1R | Q01726 | 2/20 | 0.72 |
| ▸ | GLP1R | P43220 | 4/20 | 0.64 |
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
| ▸ | CTSK | P43235 | 3/20 | 0.64 |
| ▸ | CTSH | P09668 | 1/20 | 0.64 |
| ▸ | GCGR | P47871 | 3/20 | 0.63 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.59 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.59 |
| ▸ | NMBR | P28336 | 1/20 | 0.59 |
| ▸ | GRPR | P30550 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cosyntropin SCHEMBL720535 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL29948667 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL33366 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL27555834 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL29383133 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL16649201 | 1.00 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL25356191 | 0.99 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL31252906 | 0.99 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL16649167 | 0.99 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL563374 | 0.99 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1058 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| US-20240074944-A1 | PECVD COATED PHARMACEUTICAL PACKAGING | OAKTREE FUND ADMINISTRATION, LLC | 2024-03-07 | — | — | US | claimed |
| US-20240009201-A1 | CYP11B2 BETA HYDROXYLASE INHIBITORS FOR HYPERTENSION | Mineralys Therapeutics, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| US-20230303305-A1 | METHOD AND PACKAGE FOR REDUCING THE DEGRADATION OF A DRUG AND/OR EXCIPIENT, E.G. POLYSORBATE STABILIZER, IN A PHARMACEUTICAL PRODUCT | OAKTREE FUND ADMINISTRATION, LLC | 2023-09-28 | — | — | US | claimed |
| EP-4247316-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SiO2 Medical Products, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| US-20230277415-A1 | POLYMER VIALS HAVING STANDARD EXTERNAL DIMENSIONS AND REDUCED INTERNAL VOLUME | SIO2 MEDICAL PRODUCTS, INC. | 2023-09-07 | — | — | US | claimed |
| EP-4232011-A1 | CYP11B2 BETA HYDROXYLASE INHIBITORS FOR HYPERTENSION | Mineralys Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | claimed |
| US-20230263957-A1 | ATOMIC LAYER DEPOSITION COATED PHARMACEUTICAL PACKAGING AND IMPROVED SYRINGES AND VIALS, E.G. FOR LYOPHILIZED/COLD-CHAIN DRUGS/VACCINES | OAKTREE FUND ADMINISTRATION, LLC | 2023-08-24 | — | — | US | claimed |
| EP-2776603-A1 | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS | SiO2 Medical Products, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| US-20140251859-A1 | TRILAYER COATED PHARMACEUTICAL PACKAGING | SIO2 MEDICAL PRODUCTS, INC. (US) | 2014-09-11 | — | — | US | claimed |
| WO-2014134577-A1 | PLASMA OR CVD PRE-TREATMENT FOR LUBRICATED PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS | SIO2 MEDICAL PRODUCTS, INC. (US) | 2014-09-04 | — | — | WO | claimed |
| US-20140249484-A1 | PLASMA OR CVD PRE-TREATMENT FOR LUBRICATED PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS | SIO2 MEDICAL PRODUCTS, INC. (US) | 2014-09-04 | — | — | US | claimed |
| WO-2014008138-A2 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS, INC. (US) | 2014-01-09 | — | — | WO | claimed |
| WO-2013170052-A1 | SACCHARIDE PROTECTIVE COATING FOR PHARMACEUTICAL PACKAGE | SIO2 MEDICAL PRODUCTS, INC. (US) | 2013-11-14 | — | — | WO | claimed |
| WO-2013071138-A1 | PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS | SIO2 MEDICAL PRODUCTS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20130041241-A1 | PECVD COATING METHODS FOR CAPPED SYRINGES, CARTRIDGES AND OTHER ARTICLES | OAKTREE FUND ADMINISTRATION, LLC | 2013-02-14 | — | — | US | claimed |
| WO-2004096217-A1 | USE OF N-TYPE CALCIUM CHANNEL INHIBITORS IN TREATING DEMYELINATING DISEASES | EISAI LONDON RESEARCH LABORATORIES LIMITED (GB) | 2004-11-11 | — | — | WO | claimed |
| CN-1305490-A | Improved processing for preparing schift base adducts of amines with i(o)-hydroxy aldehydes and compositions of matter based thereon | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009201-A1 | CYP11B2 BETA HYDROXYLASE INHIBITORS FOR HYPERTENSION | CYP4A11, HSD11B2, CYP11B2 | C5AR1 4772/4885MC4R 3588/4885MC5R 2015/4885 |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | C5AR1 104/4885MC4R 3677/4885MC5R 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.